Memorial Sloan Kettering Cancer Center posted on X:
“Komal Jhaveri, a breast medical oncologist at MSK, presented results from the ASCENT-07 clinical trial at the SABCS.
The phase 3 clinical trial, which tested sacituzumab govitecan-hziy as the first treatment after endocrine therapy for people with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, has shown mixed results.
In the study sacituzumab govitecan-hziy did not appear to work better than chemotherapy in terms of slowing disease progression -the main objective of the trial. However, there were intriguing signs suggesting that sacituzumab govitecan-hziy could lower the risk of death over time.
“These preliminary results related to survival are very interesting, and we need to continue following this closely,” says Dr. Jhaveri. “We did not see any new safety concerns giving sacituzumab govitecan-hziy earlier, which is encouraging, in addition to the fact that fewer patients stopped taking this drug compared with chemotherapy. In the meantime, sacituzumab govitecan-hziy remains an effective treatment option for patients whose cancer has progressed despite treatment with endocrine therapy and chemotherapy.”
Read more about the study.”
More posts about SABCS 2025 on OncoDaily.
You Can Also Read:
15 Posts Not to Miss from SABCS 2025, Part 1
20 Posts Not to Miss from SABCS 2025, Part 2
25 Posts Not to Miss from SABCS 2025, Part 3
